Description
HRS-2189 is an investigational medication currently being studied for its potential use in treating metastatic colorectal cancer. It is being evaluated in clinical trials, specifically in combination with other investigational agents (Adebrelimab and BP102). The goal of these trials is to assess the safety and effectiveness of this combination therapy for patients whose cancer has spread. As an investigational drug, HRS-2189 is not yet approved for use and its long-term effects and optimal role in treatment are still under investigation. The trials are designed to gather data on how well it works and what side effects it might cause when used with other treatments.
Mechanism of Action
The specific way HRS-2189 works (its mechanism of action) is being investigated in clinical trials. It is being studied in combination with other agents, suggesting it may target different pathways involved in cancer growth or the body's response to cancer. Further research is needed to fully understand its molecular target and how it interacts with cancer cells or the immune system.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.